Enhanced prefrontal function with pharmacotherapy on a response inhibition task in adolescent bipolar disorder.
OBJECTIVE
The aim of the current study is to determine whether pharmacotherapy normalizes cognitive circuitry function supporting voluntary behavioral inhibition in adolescent bipolar disorder.


METHODS
Healthy controls and unmedicated patients with DSM-IV adolescent bipolar disorder in manic, mixed, or hypomanic episodes were matched on demographics and IQ (n = 13 per group; mean age = 14.4 ± 2.4 years). Functional magnetic resonance imaging studies were performed at baseline and after 14 weeks, during which time patients with adolescent bipolar disorder were treated initially with second-generation antipsychotics (SGAs) followed by lamotrigine monotherapy. The primary outcome measure was a Response Inhibition Task, which involved a planned motor response, already "on the way" to execution, that had to be voluntarily inhibited by the subjects in the trials in which a stop signal was presented. There were 6 blocks, each with a predominant rate of either "go" or "stop" trials. The study was conducted from June 2006 through July 2009.


RESULTS
All patients showed significant improvement (P < .001) in both the manic and depressive symptoms from baseline. Behavioral data showed that accuracy improved over 14 weeks in patients and healthy controls. Significant time by group interaction effects for the difference between stop versus go blocks showed greater increases of activation in prefrontal (left inferior and middle frontal gyri and medial frontal gyrus bilaterally) and temporal (left superior temporal gyrus and right middle temporal gyrus) regions and greater decreases in activation in right putamen and bilateral thalamus at follow-up in the adolescent bipolar disorder group than in healthy controls. Increased ventrolateral prefrontal cortex function was related to clinical treatment response.


CONCLUSIONS
Treatment with SGAs followed by lamotrigine monotherapy enhanced prefrontal and temporal lobe activity during a Response Inhibition Task demonstrating the reversal of disorder-relevant neural circuitry dysfunction in patients with adolescent bipolar disorder. Patient performance was not slowed down with this treatment regimen.


BACKGROUND
clinicaltrials.gov Identifier: NCT00176228.
Pavuluri
Mani N
MN
Institute for Juvenile Research and Center for Cognitive Medicine, University of Illinois at Chicago, 912 South Wood St (M/C 913), Chicago, IL 60612, USA. mpavuluri@psych.uic.edu
Passarotti
Alessandra M
AM
Harral
Erin M
EM
Sweeney
John A
JA
D000293:Adolescent; D018692:Antimanic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000503:physiopathology; D001921:Brain / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D006801:Humans; D000077213:Lamotrigine; D008279:Magnetic Resonance Imaging; D008297:Male; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000502:physiology / Q000503:physiopathology; D011597:Psychomotor Performance / Q000187:drug effects* / Q000502:physiology; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D013702:Temporal Lobe / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D014227:Triazines / Q000494:pharmacology / Q000627:therapeutic use*
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D014227:Triazines; D000077213:Lamotrigine
Biol Psychiatry. 2007 Jul 15;62(2):158-67
17097071
J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7
6715741
Curr Opin Neurobiol. 2001 Dec;11(6):663-72
11741015
Biol Psychiatry. 2004 Jan 1;55(1):32-9
14706422
Psychol Rev. 2007 Jul;114(3):632-56
17638499
Neuropsychologia. 1998 Dec;36(12):1283-93
9863682
Am J Psychiatry. 2007 Jan;164(1):52-60
17202544
Arch Gen Psychiatry. 2004 Aug;61(8):781-92
15289277
Hum Brain Mapp. 2006 Dec;27(12):973-93
16683265
Psychiatry Res. 2008 Apr 15;162(3):244-55
18294820
Hum Brain Mapp. 2001 Feb;12(2):100-9
11169874
J Neurosci. 2007 Feb 21;27(8):2045-57
17314300
Bipolar Disord. 2008 May;10(3):426-31
18402630
Eur Neuropsychopharmacol. 2008 Jan;18(1):48-54
17618089
Expert Opin Pharmacother. 2002 Oct;3(10):1513-9
12387697
Eur J Neurosci. 2003 Jun;17(12):2648-58
12823472
Biol Psychiatry. 2005 Nov 15;58(10):763-9
16310510
Br J Psychiatry. 1978 Nov;133:429-35
728692
Arch Gen Psychiatry. 2000 Mar;57(3):270-6
10711913
Medscape J Med. 2008;10(9):211
19008973
Am J Psychiatry. 2003 Jul;160(7):1345-7
12832254
J Exp Psychol Hum Percept Perform. 1984 Apr;10(2):276-91
6232345
Hum Brain Mapp. 2005 May;25(1):35-45
15846821
Neuroimage. 2001 Feb;13(2):250-61
11162266
J Child Adolesc Psychopharmacol. 2009 Feb;19(1):75-82
19232025
J Clin Psychiatry. 2000 Nov;61(11):841-50
11105737
Neuropharmacology. 2007 Feb;52(2):598-605
17070874
J Affect Disord. 1998 Nov;51(2):93-100
10743842
Annu Rev Neurosci. 1986;9:357-81
3085570
Am J Psychiatry. 2007 Feb;164(2):309-17
17267795
Neuroimage. 2002 Jun;16(2):449-53
12030830
J Clin Psychiatry. 2008;69 Suppl 4:26-36
18533766
Cereb Cortex. 1999 Oct-Nov;9(7):745-53
10554997
Am J Psychiatry. 2005 Sep;162(9):1697-705
16135630
Am J Psychiatry. 2006 Feb;163(2):286-93
16449483